Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · see citing works

CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

Bladé, J., Samson, D., Reece, D. E., Apperley, J. F., Björkstrand, B., Gahrton, G., Gertz, M. A., Giralt, S. A., Jagannath, S., & Vesole, D. H. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,516 · see citing works

Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450 · see citing works

Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233 · see citing works

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy

Hideshima, T., Chauhan, D., Shima, Y., Raje, N. S., Davies, F. E., Tai, Y., Treon, S. P., Lin, B. K., Schlossman, R. L., Richardson, P. G. G., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 874 · see citing works

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

Palumbo, A. P., Rajkumar, S. V., Dimopoulos, M. A., Richardson, P. G. G., Miguel, J. F. S., Barlogie, B., Harousseau, J., Zonder, J. A., Cavo, M., Zangari, M., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2405062 · Cited by 840 · see citing works

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

Miguel, J. F. S., Weisel, K. C., Moreau, P., Lacy, M. Q., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70380-2 · Cited by 800 · see citing works

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.

Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L. M., Ocampo, C. J., Patterson, R. T., Stirling, D., & Kaplan, G. (1999) · PubMed · Cited by 729 · see citing works

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.196 · Cited by 721 · see citing works

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N. C., Treon, S. P., & Anderson, K. C. (2002) · Blood · doi:10.1182/blood.v99.12.4525 · Cited by 669 · see citing works

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

Siegel, D. S. D., Martin, T. G., Wang, M. L., Vij, R., Jakubowiak, A. J., Lonial, S., Trudel, S., Kukreti, V., Bahlis, N. J., Alsina, M., et al. (2012) · Blood · doi:10.1182/blood-2012-05-425934 · Cited by 656 · see citing works

Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That Are Potent Inhibitors of TNF-α

Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L.-M., Ocampo, C. J., Patterson, R. T., Stirling, D., & Kaplan, G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.380 · Cited by 654 · see citing works

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

Quach, H., Ritchie, D., Stewart, A. K., Neeson, P. J., Harrison, S. J., Smyth, M. J., & Prince, H. M. (2009) · Leukemia · doi:10.1038/leu.2009.236 · Cited by 600 · see citing works

Clinical Course of Patients With Relapsed Multiple Myeloma

Kumar, S. K., Therneau, T. M., Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Rajkumar, S. V., Fonseca, R., Witzig, T. E., Lust, J. A., Larson, D. R., et al. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.7.867 · Cited by 365 · see citing works

Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma

Lacy, M. Q., Hayman, S. R., Gertz, M. A., Dispenzieri, A., Buadi, F., Kumar, S., Greipp, P. R., Lust, J. A., Russell, S. J., Dingli, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6802 · Cited by 317 · see citing works

Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma

Schey, S., Fields, P. A., Bartlett, J. B., Clarke, I., Ashan, G., Knight, R., Streetly, M. J., & Dalgleish, A. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.052 · Cited by 312 · see citing works

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2

Munshi, N. C., Anderson, K. C., Bergsagel, P. L., Shaughnessy, J. D., Palumbo, A. P., Durie, B. G. M., Fonseca, R., Stewart, A. K., Harousseau, J., Dimopoulos, M. A., et al. (2011) · Blood · doi:10.1182/blood-2010-10-300970 · Cited by 312 · see citing works

Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival

Avet‐Loiseau, H., Attal, M., Campion, L., Caillot, D., Hulin, C., Marit, G., Stoppa, A., Voillat, L., Wetterwald, M., Pegourié, B., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.5726 · Cited by 223 · see citing works

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

Lacy, M. Q., Allred, J. B., Gertz, M. A., Hayman, S. R., Short, K. D., Buadi, F., Dispenzieri, A., Kumar, S., Greipp, P. R., Lust, J. A., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348896 · Cited by 222 · see citing works

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02

Leleu, X. P., Attal, M., Arnulf, B., Moreau, P., Traullé, C., Marit, G., Mathiot, C., Petillon, M. O., Macro, M., Roussel, M., et al. (2013) · Blood · doi:10.1182/blood-2012-09-452375 · Cited by 206 · see citing works

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

Lacy, M. Q., Hayman, S. R., Gertz, M. A., Short, K. D., Dispenzieri, A., Kumar, S., Greipp, P. R., Lust, J. A., Russell, S. J., Dingli, D., et al. (2010) · Leukemia · doi:10.1038/leu.2010.190 · Cited by 197 · see citing works

Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism

Escoubet‐Lozach, L., Lin, I.-L., Jensen-Pergakes, K., Brady, H. A., Gandhi, A. K., Schafer, P. H., Muller, G. W., Worland, P. J., Chan, K. W. H., & Verhelle, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4898 · Cited by 173 · see citing works

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

Richardson, P. G. G., Siegel, D. S. D., Baz, R., Kelley, S. L., Munshi, N. C., Laubach, J. P., Sullivan, D. M., Alsina, M., Schlossman, R. L., Ghobrial, I. M., et al. (2012) · Blood · doi:10.1182/blood-2012-08-450742 · Cited by 162 · see citing works

New Drugs for Myeloma

Richardson, P. G. G., Mitsiades, C. S., Schlossman, R. L., Munshi, N. C., & Anderson, K. C. (2007) · The Oncologist · doi:10.1634/theoncologist.12-6-664 · Cited by 157 · see citing works

Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1

Anderson, G., Gries, M., Kurihara, N., Honjo, T., Anderson, J., Donnenberg, V. S., Donnenberg, A. D., Ghobrial, I. M., Mapara, M. Y., Stirling, D., et al. (2005) · Blood · doi:10.1182/blood-2005-08-3450 · Cited by 148 · see citing works

Treatment Options for Relapsed and Refractory Multiple Myeloma

Lonial, S., Mitsiades, C. S., & Richardson, P. G. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1805 · Cited by 126 · see citing works

Alternate day pomalidomide retains anti‐myeloma effect with reduced adverse events and evidence of in vivo immunomodulation

Streetly, M. J., Gyertson, K., Daniel, Y., Zeldis, J. B., Kazmi, M. A., & Schey, S. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07013.x · Cited by 125 · see citing works

Phase II Trials in Journal of Clinical Oncology

Cannistra, S. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1811 · Cited by 102 · see citing works

Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases

Xu, Y., Li, J., Ferguson, G. D., Mercurio, F., Khambatta, G., Morrison, L., Lopez‐Girona, A., Corral, L. G., Webb, D. R., Bennett, B. L., et al. (2009) · Blood · doi:10.1182/blood-2009-02-200543 · Cited by 87 · see citing works

Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study

Larocca, A., Montefusco, V., Bringhen, S., Rossi, D., Crippa, C., Mina, R., Galli, M., Marcatti, M., Verde, G. L., Giuliani, N., et al. (2013) · Blood · doi:10.1182/blood-2013-03-488676 · Cited by 85 · see citing works

Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications.

Hervé, A., Florence, M., Philippe, M., Michel, A., Thierry, F., Kenneth, A., Jean-Luc, H., Nikhil, M., & Stéphane, M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8435 · Cited by 79 · see citing works

The use of novel agents in the treatment of relapsed and refractory multiple myeloma

Laubach, J. P., Mahindra, A. K., Mitsiades, C. S., Schlossman, R. L., Munshi, N. C., Ghobrial, I. M., Carreau, N. A., Hideshima, T., Anderson, K. C., & Richardson, P. G. G. (2009) · Leukemia · doi:10.1038/leu.2009.179 · Cited by 78 · see citing works

A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma

Lilienfeld‐Toal, M. V., Hahn‐Ast, C., Furkert, K., Hoffmann, F., Naumann, R., Bargou, R. C., Cook, G., & Glasmacher, A. G. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01121.x · Cited by 78 · see citing works

Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis

Koh, K.-R. (2004) · Blood · doi:10.1182/blood-2004-03-0828 · Cited by 57 · see citing works

ClaPD (Clarithromycin/[Biaxin®], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma

Mark, T. M., Rodriguez, M., Shah, M. B., Quinn, R., Campbell, J., Abdullah, R., Pearse, R. N., Zafar, F., Pekle, K. A., Mignott, P., et al. (2011) · Blood · doi:10.1182/blood.v118.21.635.635 · Cited by 42 · see citing works

A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma

Shah, J. J., Stadtmauer, E. A., Abonour, R., Cohen, A. D., Bensinger, W., Gasparetto, C., Kaufman, J. L., Lentzsch, S., Vogl, D. T., Orlowski, R. Z., et al. (2012) · Blood · doi:10.1182/blood.v120.21.74.74 · Cited by 31 · see citing works

ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma

Mark, T. M., Boyer, A. S., Rossi, A., Shah, M. B., Pearse, R. N., Zafar, F., Pekle, K. A., Tegnestam, L., Sacris, E., Greenberg, J., et al. (2012) · Blood · doi:10.1182/blood.v120.21.77.77 · Cited by 20 · see citing works

Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT).

Vij, R., Richardson, P. G. G., Jagannath, S., Siegel, D. S. D., Baz, R., Srinivasan, S. S., Larkins, G., Zaki, M. H., Hussein, M. A., & Anderson, K. C. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.8016 · Cited by 18 · see citing works

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma

Mark, T. M., Forsberg, P. A., Rossi, A., Pearse, R. N., Pekle, K. A., Perry, A., Boyer, A. S., Tegnestam, L., Jayabalan, D. S., Coleman, M., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018028027 · Cited by 16 · see citing works

Pomalidomide Cyclophosphamide and Prednisone (PCP) Treatment for Relapsed/Refractory Multiple Myeloma

Palumbo, A. P., Larocca, A., Montefusco, V., Rossi, D., Carella, A. M., Mina, R., Crippa, C., Sciacca, M., Galli, M., Scalabrini, D. R., et al. (2012) · Blood · doi:10.1182/blood.v120.21.446.446 · Cited by 14 · see citing works

Oral Weekly Cyclophosphamide in Combination with Pomalidomide and Dexamethasone for Relapsed and Refractory Myeloma: Report of the Dose Escalation Cohort

Baz, R., Shain, K. H., Alsina, M., Nardelli, L. A., Nishihori, T., Ochoa, L., Martin, T. G., Jagannath, S., Dalton, W. S., & Sullivan, D. M. (2012) · Blood · doi:10.1182/blood.v120.21.4062.4062 · Cited by 13 · see citing works

A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma.

Berenson, J. R., Hilger, J. D., Klein, L. M., Eshaghian, S., Nassir, Y., Swift, R. A., & Vescio, R. A. (2012) · Blood · doi:10.1182/blood.v120.21.2979.2979 · Cited by 12 · see citing works

MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Richardson, P. G. G., Hofmeister, C. C., Siegel, D. S. D., Lonial, S., Zaki, M. H., Ye, H., Shah, S., Wang, J., & Anderson, K. C. (2012) · Blood · doi:10.1182/blood.v120.21.727.727 · Cited by 12 · see citing works

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy

Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943.h8002943_2943_2950

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117 · see citing works

Diagnosis and Management of Multiple Myeloma

Cowan, A. J., Green, D. J., Kwok, M., Lee, S., Coffey, D. G., Holmberg, L., Tuazon, S. A., Gopal, A. K., & Libby, E. N. (2022) · JAMA · doi:10.1001/jama.2022.0003 · Cited by 1,054 · see citing works

Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883 · see citing works

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Lonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854 · see citing works

Multiple Myeloma: Diagnosis and Treatment

Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812 · see citing works

Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management

Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 802 · see citing works

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Attal, M., Richardson, P. G. G., Rajkumar, S. V., Miguel, J. F. S., Beksaç, M., Špıčka, I., Leleu, X. P., Schjesvold, F. H., Moreau, P., Dimopoulos, M. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32556-5 · Cited by 648 · see citing works

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

Dimopoulos, M. A., Dytfeld, D., Grosicki, S., Moreau, P., Takezako, N., Hori, M., Leleu, X. P., LeBlanc, R., Suzuki, K., Raab, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805762 · Cited by 540 · see citing works

Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management

Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534 · see citing works

Multiple myeloma: 2016 update on diagnosis, risk‐stratification, and management

Rajkumar, S. V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24402 · Cited by 460 · see citing works

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Chari, A., Suvannasankha, A., Fay, J. W., Arnulf, B., Kaufman, J. L., Ifthikharuddin, J. J., Weiss, B. M., Krishnan, A. Y., Lentzsch, S., Comenzo, R. L., et al. (2017) · Blood · doi:10.1182/blood-2017-05-785246 · Cited by 444 · see citing works

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

Usmani, S. Z., Weiss, B. M., Plesner, T., Bahlis, N. J., Belch, A., Lonial, S., Lokhorst, H. M., Voorhees, P. M., Richardson, P. G., Chari, A., et al. (2016) · Blood · doi:10.1182/blood-2016-03-705210 · Cited by 407 · see citing works

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Richardson, P. G., Oriol, A., Beksac, M., Liberati, A. M., Galli, M., Schjesvold, F., Lindsay, J., Weisel, K., White, D., Facon, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30152-4 · Cited by 386 · see citing works

Multiple myeloma current treatment algorithms

Rajkumar, S. V., & Kumar, S. K. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00359-2 · Cited by 362 · see citing works

Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature

Argyriou, A. A., Kyritsis, A. P., Makatsoris, T., & Kalofonos, H. P. (2014) · Cancer Management and Research · doi:10.2147/cmar.s44261 · Cited by 274 · see citing works

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

Spencer, A. G., Lentzsch, S., Weisel, K. C., Avet‐Loiseau, H., Mark, T. M., Špıčka, I., Masszi, T., Lauri, B., Levin, M., Bosi, A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.194118 · Cited by 269 · see citing works

Panobinostat for the Treatment of Multiple Myeloma

Laubach, J. P., Moreau, P., Miguel, J. F. S., & Richardson, P. G. G. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0530 · Cited by 260 · see citing works

Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience

Holstein, S. A., & McCarthy, P. L. (2017) · Drugs · doi:10.1007/s40265-017-0689-1 · Cited by 258 · see citing works

Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial

Trudel, S., Lendvai, N. K., Popat, R., Voorhees, P. M., Reeves, B., Libby, E. N., Richardson, P. G. G., Anderson, L. D., Sutherland, H. J., Yong, K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30576-x · Cited by 251 · see citing works

Multiple Myeloma: Available Therapies and Causes of Drug Resistance

Pinto, V., Bergantim, R., Caires, H. R., Seca, H., Guimarães, J. E., & Vasconcelos, M. H. (2020) · Cancers · doi:10.3390/cancers12020407 · Cited by 233 · see citing works

Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management

Rajkumar, S. V. (2018) · American Journal of Hematology · doi:10.1002/ajh.25117 · Cited by 217 · see citing works

Multiple myeloma: 2014 Update on diagnosis, risk‐stratification, and management

Rajkumar, S. V. (2014) · American Journal of Hematology · doi:10.1002/ajh.23810 · Cited by 211 · see citing works

Current treatment landscape for relapsed and/or refractory multiple myeloma

Dimopoulos, M. A., Richardson, P. G. G., Moreau, P., & Anderson, K. C. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.200 · Cited by 195 · see citing works

Novel agents in the treatment of multiple myeloma: a review about the future

Naymagon, L., & Abdul‐Hay, M. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0282-1 · Cited by 177 · see citing works

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

Sanchez, L. J., Wang, Y., Siegel, D. S. D., & Wang, M. L. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0283-0 · Cited by 178 · see citing works

Treatment of relapsed and refractory multiple myeloma

Sonneveld, P., & Broijl, A. (2016) · Haematologica · doi:10.3324/haematol.2015.129189 · Cited by 176 · see citing works

Progress and Paradigms in Multiple Myeloma

Anderson, K. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0625 · Cited by 171 · see citing works

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

Dimopoulos, M. A., Palumbo, A. P., Corradini, P., Cavo, M., Delforge, M., Raimondo, F. D., Weisel, K. C., Oriol, A., Hansson, M., Vacca, A., et al. (2016) · Blood · doi:10.1182/blood-2016-02-700872 · Cited by 165 · see citing works

Myeloma today: Disease definitions and treatment advances

Rajkumar, S. V. (2015) · American Journal of Hematology · doi:10.1002/ajh.24236 · Cited by 159 · see citing works

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma

Baz, R., Martin, T. G., Lin, H., Zhao, X., Shain, K. H., Cho, H. J., Wolf, J. L., Mahindra, A. K., Chari, A., Sullivan, D. M., et al. (2016) · Blood · doi:10.1182/blood-2015-11-682518 · Cited by 159 · see citing works

Treatment options for relapsed and refractory multiple myeloma

Nooka, A. K., Kastritis, E., Dimopoulos, M. A., & Lonial, S. (2015) · Blood · doi:10.1182/blood-2014-11-568923 · Cited by 156 · see citing works

Nephrotoxicity in cancer treatment: An overview

Santos, M. L. C., de Brito, B. B., da Silva, F. A. F., Botelho, A. C. D. S., & de Melo, F. F. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i4.190 · Cited by 157 · see citing works

Second primary malignancies in multiple myeloma: an overview and IMWG consensus

Musto, P., Anderson, K. C., Attal, M., Richardson, P. G. G., Badros, A., Hou, J., Comenzo, R. L., Du, J., Durie, B. G. M., Miguel, J. F. S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw606 · Cited by 153 · see citing works

The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

Spencer, A., Yoon, S.-S., Harrison, S. J., Morris, S. R., Smith, D. A., Brigandi, R. A., Gauvin, J., Kumar, R., Opalinska, J. B., & Chen, C. (2014) · Blood · doi:10.1182/blood-2014-03-559963 · Cited by 142 · see citing works

Therapy for Relapsed Multiple Myeloma

Dingli, D., Ailawadhi, S., Bergsagel, P. L., Buadi, F. K., Dispenzieri, A. A., Fonseca, R., Gertz, M. A., Gonsalves, W. I., Hayman, S. R., Kapoor, P., et al. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.01.003 · Cited by 140 · see citing works

Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD

Usmani, S. Z., Ahmadi, T., Ng, Y., Lam, A., Desai, A. G., Potluri, R. C., & Mehra, M. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0104 · Cited by 139 · see citing works

Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide

Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137 · see citing works

Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets

Sehgal, K., Das, R., Zhang, L., Verma, R., Deng, Y., Kocoglu, M. H., Vasquez, J. C., Koduru, S. V., Ren, Y., Wang, M., et al. (2015) · Blood · doi:10.1182/blood-2014-11-611426 · Cited by 134 · see citing works

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

Richardson, P. G. G., Hungria, V., Yoon, S., Beksaç, M., Dimopoulos, M. A., Elghandour, A., Wiktor-Jędrzejczak, W., Guenther, A., Nakorn, T. N., Siritanaratkul, N., et al. (2015) · Blood · doi:10.1182/blood-2015-09-665018 · Cited by 133 · see citing works

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

Dimopoulos, M. A., Leleu, X. P., Palumbo, A. P., Moreau, P., Delforge, M., Cavo, M., Ludwig, H., Morgan, G. J., Davies, F. E., Sonneveld, P., et al. (2014) · Leukemia · doi:10.1038/leu.2014.60 · Cited by 123 · see citing works

Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance

Song, Y., Li, S., Ray, A., Das, D. S., Qi, J., Samur, M., Tai, Y., Munshi, N. C., Carrasco, R. D., Chauhan, D., et al. (2017) · Oncogene · doi:10.1038/onc.2017.172 · Cited by 112 · see citing works

Current Trends of Renal Impairment in Multiple Myeloma

Yadav, P., Cook, M. A., & Cockwell, P. (2015) · Kidney Diseases · doi:10.1159/000442511 · Cited by 111 · see citing works

Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma

Martin, T. G., Strickland, S. A., Glenn, M. J., Charpentier, E., Guillemin, H., Hsu, K., & Mikhael, J. R. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0198-4 · Cited by 109 · see citing works

Management of multiple myeloma in the relapsed/refractory patient

Sonneveld, P. (2017) · Hematology · doi:10.1182/asheducation-2017.1.508 · Cited by 108 · see citing works

Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity

Cornell, R. F., & Kassim, A. A. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.307 · Cited by 101 · see citing works

Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies

Li, W., Garcia, D. A., Cornell, R. F., Gailani, D., Laubach, J. P., Maglio, M. E., Richardson, P. G. G., & Moslehi, J. J. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3350 · Cited by 102 · see citing works

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results

Leleu, X. P., Karlin, L., Macro, M., Hulin, C., Garderet, L., Roussel, M., Arnulf, B., Pegourié, B., Kolb, B., Stoppa, A. M., et al. (2015) · Blood · doi:10.1182/blood-2014-11-612069 · Cited by 100 · see citing works

Bispecific Antibodies in Multiple Myeloma: Present and Future

Lancman, G., Sastow, D. L., Cho, H. J., Jagannath, S., Madduri, D., Parekh, S. S., Richard, S., Richter, J. R., Sanchez, L. J., & Chari, A. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0028 · Cited by 101 · see citing works

A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis

Palladini, G. O., Milani, P., Foli, A., Basset, M., Russo, F., Perlini, S., & Merlini, G. (2017) · Blood · doi:10.1182/blood-2016-12-756528 · Cited by 93 · see citing works

Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century

Pulte, D. D., Jansen, L., Castro, F. A., Emrich, K., Katalinic, A., Holleczek, B., Brenner, H., & the GEKID Cancer Survival Working Group (2015) · British Journal of Haematology · doi:10.1111/bjh.13537 · Cited by 92 · see citing works

ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells

Yamamoto, J., Suwa, T., Murase, Y., Tateno, S., Mizutome, H., Asatsuma‐Okumura, T., Shimizu, N., Kishi, T., Momose, S., Kizaki, M., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0645-3 · Cited by 90 · see citing works

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

Mikhael, J. R., Richardson, P. G. G., Usmani, S. Z., Raje, N. S., Bensinger, W., Karanes, C., Campana, F., Kanagavel, D., Dubin, F., Liu, Q., et al. (2019) · Blood · doi:10.1182/blood-2019-02-895193 · Cited by 90 · see citing works

Promising therapies in multiple myeloma

Bianchi, G., Richardson, P. G. G., & Anderson, K. C. (2015) · Blood · doi:10.1182/blood-2015-03-575365 · Cited by 86 · see citing works

Academic, Foundation, and Industry Collaboration in Finding New Therapies

Ramsey, B. W., Nepom, G. T., & Lonial, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1612575 · Cited by 87 · see citing works

Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study

Richardson, P. G. G., Bringhen, S., Voorhees, P. M., Plesner, T., Mellqvist, U., Reeves, B., Paba‐Prada, C. E., Zubair, H., Byrne, C., Chauhan, D., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30044-2 · Cited by 83 · see citing works

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

Siegel, D. S. D., Schiller, G. J., Samaras, C. J., Sébag, M., Berdeja, J. G., Ganguly, S., Matous, J., Song, K., Seet, C. S., Talamo, G., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0813-1 · Cited by 84 · see citing works

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma

Paludo, J., Mikhael, J. R., LaPlant, B. R., Halvorson, A. E., Kumar, S. K., Gertz, M. A., Hayman, S. R., Buadi, F. K., Dispenzieri, A. A., Lust, J. A., et al. (2017) · Blood · doi:10.1182/blood-2017-05-782961 · Cited by 78 · see citing works

Approach to chemotherapy-associated thrombosis

Oppelt, P., Betbadal, A., & Nayak, L. V. (2015) · Vascular Medicine · doi:10.1177/1358863x14568705 · Cited by 74 · see citing works

A phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma ( NPI ‐0052‐107): final study results

Spencer, A. G., Harrison, S. J., Zonder, J. A., Badros, A. Z., Laubach, J. P., Bergin, K., Khot, A. S., Zimmerman, T. M., Chauhan, D., Levin, N., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14987 · Cited by 73 · see citing works

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone

Dimopoulos, M. A., Weisel, K. C., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Moreau, P., Baños, A., Oriol, A., Garderet, L., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.117077 · Cited by 72 · see citing works

Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design

Moreau, P., Dimopoulos, M. A., Yong, K., Mikhael, J. R., Risse, M., Asset, G., & Martin, T. G. (2019) · Future Oncology · doi:10.2217/fon-2019-0431 · Cited by 72 · see citing works

Isatuximab Plus Pomalidomide/Dexamethasone Versus Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma: Icaria Phase Iii Study Design

Richardson, P. G. G., Attal, M., Campana, F., Le-Guennec, S., Hui, A., Risse, M., Corzo, K. P., & Anderson, K. C. (2017) · Future Oncology · doi:10.2217/fon-2017-0616 · Cited by 71 · see citing works

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

Jakubowiak, A. J., Jasielec, J. K., Rosenbaum, C. A., Cole, C. E., Chari, A., Mikhael, J. R., Nam, J., McIver, A., Severson, E., Stephens, L. A., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.15969 · Cited by 69 · see citing works

Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools

Fotiou, D., Gavriatopoulou, M., & Terpos, E. (2020) · Cancers · doi:10.3390/cancers12010191 · Cited by 69 · see citing works

Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial

Dimopoulos, M. A., Weisel, K. C., van de Donk, N. W. C. J., Ramasamy, K., Gamberi, B., Streetly, M. J., Offidani, M., Bridoux, F., de la Rubia, J., Mateos, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.1742 · Cited by 69 · see citing works

How I treat first relapse of myeloma

Harousseau, J. L., & Attal, M. (2017) · Blood · doi:10.1182/blood-2017-03-726703 · Cited by 66 · see citing works

Pain in cancer survivors; filling in the gaps

Brown, M. R. D., & Farquhar-Smith, P. W. (2017) · British Journal of Anaesthesia · doi:10.1093/bja/aex202 · Cited by 68 · see citing works

A Phase 1 and 2 study of Filanesib alone and in combination with low‐dose dexamethasone in relapsed/refractory multiple myeloma

Shah, J. J., Kaufman, J. L., Zonder, J. A., Cohen, A. D., Bensinger, W., Hilder, B. W., Rush, S. A., Walker, D. H., Tunquist, B. J., Litwiler, K. S., et al. (2017) · Cancer · doi:10.1002/cncr.30892 · Cited by 65 · see citing works

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

Garderet, L., Kuhnowski, F., Berge, B., Roussel, M., Escoffre‐Barbe, M., Lafon, I., Facon, T. T. F., Leleu, X. P., Karlin, L., Perrot, A., et al. (2018) · Blood · doi:10.1182/blood-2018-07-863829 · Cited by 65 · see citing works

A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival

Kazandjian, D. G., & Landgren, O. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.10.008 · Cited by 63 · see citing works

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

Dimopoulos, M. A., Weisel, K. C., Moreau, P., Anderson, L. D., White, D. J., Miguel, J. F. S., Sonneveld, P., Engelhardt, M. M., Jenner, M. W., Corso, A., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01021-3 · Cited by 64 · see citing works

Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011–2019 oncology clinic electronic health record data

Braunlin, M., Belani, R., Buchanan, J., Wheeling, J. T., & Kim, C. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1827253 · Cited by 63 · see citing works

Pomalidomide in combination with dexamethasone results in synergistic anti‐tumour responses in pre‐clinical models of lenalidomide‐resistant multiple myeloma

Rychak, E., Mendy, D., Shi, T., Ning, Y., Leisten, J. C., Lu, L., Miller, K., Narla, R. K., Orlowski, R. Z., Raymon, H. K., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13905 · Cited by 60 · see citing works

Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma

Wanchoo, R., Abudayyeh, A., Doshi, M. D., Edeani, A., Glezerman, I. G., Monga, D., Rosner, M. H., & Jhaveri, K. D. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06100616 · Cited by 60 · see citing works

Developing next generation immunomodulatory drugs and their combinations in multiple myeloma

Thakurta, A., Pierceall, W. E., Amatangelo, M. D., Flynt, E., & Agarwal, A. (2021) · Oncotarget · doi:10.18632/oncotarget.27973 · Cited by 57 · see citing works

Current treatments for renal failure due to multiple myeloma

Gavriatopoulou, M., Terpos, E., Kastritis, E., & Dimopoulos, M. A. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1236915 · Cited by 54 · see citing works

Cereblon binding molecules in multiple myeloma

Kortüm, K. M., Zhu, Y. X., Shi, C., Jedlowski, P. M., & Stewart, A. K. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.03.003 · Cited by 53 · see citing works

p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma

Hideshima, T., Cottini, F., Nozawa, Y., Seo, H., Ohguchi, H., Samur, M., Cirstea, D. D., Mimura, N., Iwasawa, Y., Richardson, P. G. G., et al. (2017) · Blood · doi:10.1182/blood-2016-09-738500 · Cited by 53 · see citing works

Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options

Ramasamy, K., Gay, F., Weisel, K. C., Zweegman, S., Mateos, M., & Richardson, P. G. G. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100808 · Cited by 54 · see citing works

Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma

Miguel, J. F. S., Weisel, K. C., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Moreau, P., Baños, A., Oriol, A., Garderet, L., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.125864 · Cited by 51 · see citing works

Monoclonal antibodies — A new era in the treatment of multiple myeloma

Jelı́nek, T., & Hájek, R. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.08.004 · Cited by 50 · see citing works

Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma

Krishnan, A. Y., Kapoor, P., Palmer, J. M., Tsai, N., Kumar, S. K., Lonial, S., Htut, M., Karanes, C., Nathwani, N., Rosenzweig, M. A., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0038-8 · Cited by 51 · see citing works

Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD^®immunomodulatory drug pomalidomide

Das, D. S., Ray, A., Song, Y., Richardson, P., Trikha, M., Chauhan, D., & Anderson, K. C. (2015) · British Journal of Haematology · doi:10.1111/bjh.13780 · Cited by 49 · see citing works

Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel

Stefano, V. D., Larocca, A., Carpenedo, M., Cavo, M., Raimondo, F. D., Falanga, A., Offidani, M., Petrucci, M. T., Ruggeri, M., Santi, R. M., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.280893 · Cited by 50 · see citing works

Paraproteinemic neuropathies

Raheja, D., Specht, C., & Simmons, Z. (2014) · Muscle & Nerve · doi:10.1002/mus.24471 · Cited by 49 · see citing works

Multiple Myeloma: From Front-Line to Relapsed Therapies

Moreau, P., & Touzeau, C. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e504 · Cited by 48 · see citing works

The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma

Schmitz, S., Maguire, Á., Morris, J., Ruggeri, K., Haller, E., Kuhn, I. L., Leahy, J., Homer, N., Khan, A., Bowden, J., et al. (2018) · BMC Medical Research Methodology · doi:10.1186/s12874-018-0509-7 · Cited by 48 · see citing works

New Agents in Multiple Myeloma: An Examination of Safety Profiles

Bringhen, S., de Wit, E., & Dimopoulos, M. A. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.05.003 · Cited by 49 · see citing works

Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure

Siegel, D. S., Schiller, G. J., Song, K. W., Agajanian, R., Stockerl‐Goldstein, K., Kaya, H., Sebag, M., Samaras, C., Malek, E., Talamo, G., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16213 · Cited by 46 · see citing works

Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma

Dimopoulos, M.-A., Richardson, P., & Lonial, S. (2022) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2022.01.011 · Cited by 46 · see citing works

Emerging drugs and combinations to treat multiple myeloma

Larocca, A., Mina, R., Gay, F., Bringhen, S., & Boccadoro, M. (2017) · Oncotarget · doi:10.18632/oncotarget.19269 · Cited by 44 · see citing works

Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed–refractory Multiple Myeloma in the United States

Pelligra, C. G., Parikh, K., Guo, S., Chandler, C., Mouro, J. L., Abouzaid, S., & Ailawadhi, S. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.08.010 · Cited by 46 · see citing works

Mechanisms of lenalidomide sensitivity and resistance

Martínez-Høyer, S., & Karsan, A. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.09.196 · Cited by 45 · see citing works

Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study

Kelly, K. R., Ailawadhi, S., Siegel, D. S., Heffner, L. T., Somlo, G., Jagannath, S., Zimmerman, T. M., Munshi, N. C., Madan, S., Chanan-Khan, A., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00208-8 · Cited by 46 · see citing works

Population pharmacokinetics of pomalidomide

Li, Y., Xu, Y., Liu, L., Wang, X., Palmisano, M., & Zhou, S. Y. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.455 · Cited by 44 · see citing works

Immunotherapy in Multiple Myeloma

Soekojo, C. Y., Ooi, M. G. M., Mel, S. D., & Chng, W. J. (2020) · Cells · doi:10.3390/cells9030601 · Cited by 46 · see citing works

Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy

Ríos, R., Agustin, M.-G., Alarcón-Payer, C., Dolores, S.-R., María, V. D. D. L. G. A., Collado, C. G., Alberto, J. M., Manuel, J. C., & Barrera, J. C. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s115456 · Cited by 42 · see citing works

New Drugs in Multiple Myeloma

Kunacheewa, C., & Orlowski, R. Z. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-112017-091045 · Cited by 42 · see citing works

Pathogenesis and treatment of multiple myeloma

Yang, P., Qu, Y., Wang, M., Chu, B., Chen, W., Zheng, Y., Niu, T., & Qian, Z. (2022) · MedComm · doi:10.1002/mco2.146 · Cited by 42 · see citing works

The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial

Malek, E., Rana, P. S., Swamydas, M., Daunov, M., Miyagi, M., Murphy, E., Ignatz-Hoover, J. J., Metheny, L. L., Kim, S.-J., & Driscoll, J. J. (2024) · Nature Communications · doi:10.1038/s41467-024-51442-2 · Cited by 43 · see citing works

Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results

Richardson, P. G. G., Siegel, D. S. D., Vij, R., Hofmeister, C. C., Jagannath, S., Chen, C. I., Lonial, S., Jakubowiak, A. J., Bahlis, N. J., Baz, R., et al. (2011) · Blood · doi:10.1182/blood.v118.21.634.634 · Cited by 34 · see citing works

A new treatment option for relapsed and refractory MM

(2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.11 · Cited by 1 · see citing works

Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial.

Siegel, D. S. D., Richardson, P. G. G., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C. I., Lonial, S., Jakubowiak, A. J., Bahlis, N. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8588 · Cited by 7 · see citing works

Safety and efficacy of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM).

Berenson, J. R., Stampleman, L. V., Bessudo, A., Rosen, P. J., Klein, L. M., Woliver, T. B. S., Flam, M. S., Eshaghian, S., Nassir, Y., Swift, R. A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8591 · Cited by 2 · see citing works

A phase 1/2 study of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM).

Berenson, J. R., Klein, L. M., Rosen, P. J., Woliver, T. B. S., Eshaghian, S., Nassir, Y., Swift, R. A., & Vescio, R. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.e19586 · Cited by 1 · see citing works